The Need for Better Endpoints: Towards a More Efficient Drug Development in Oncology

October 4, 2012

IDDI organized a webinar on THE NEED FOR BETTER CLINICAL ENDPOINTS : TOWARDS A MORE EFFICIENT DRUG DEVELOPMENT IN ONCOLOGY

The increasing number of potential targeted therapies puts a pressure on the ability to evaluate the efficacy of candidate treatments in a fast way. A key element in the evaluation process is the use of sensitive and relevant clinical endpoints.

  • This webinar reviewed  a range of established and novel endpoints that could be considered for use in the cancer trials.The speakers discussed potential benefits and risks of the use of the different endpoints.

VIEW THE RECORDING OF THE WEBINAR HERE

TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL OUT THE FORM BELOW

The Need for Better Endpoints: Towards a More Efficient Drug Development in Oncology

To access the presentation of this on-demand webinar, register to the right

Contents:

  • The increasing number of potential targeted therapies puts a pressure on the ability to evaluate the efficacy of candidate treatments in a fast way. A key element in the evaluation process is the use of sensitive and relevant clinical endpoints.
  • This webinar reviewed  a range of established and novel endpoints that could be considered for use in the cancer trials. The speakers discussed potential benefits and risks of the use of the different endpoints.

Speakers:

  • Prof Tomasz Burzykowski, VP of Research at IDDI since 2009. Tomasz is Research Professor of Biostatistics/Bioinformatics at the Center for Statistics of Hasselt University since 2002 and serves as Associate Editor for Biometrics.
  • Everardo D. Saad, Founder of DENDRIX, and Senior Oncology Consultant IDDI . Everardo D. Saad is the scientific director and chair at DENDRIX, a medical education, communications and research company based in Sao Paulo, Brazil. He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston. After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.

 

Presentation of the Webinar: The Need for Better Endpoints: Towards a More Efficient Drug Development in Oncology

To access the presentation of this on-demand webinar, please fill out this form.

By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

I authorize IDDI to use my data to contact me for commercial purposes. More information
Powered by Atypic ®

IDDI